Drug Search Results

KI-67

Alternative Names: ki-67, ki67, ki 67
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

Ki-67 may be considered as a valuable biomarker in breast cancer patients.

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date
I-share	N/A	Recruiting	Cervical Cancer\|Uterine Cancer	2027-02-01
ChiCTR2100054369	N/A	Recruiting	Adenocarcinoma	2023-12-31
ChiCTR2100054094	N/A	Recruiting	Liver Cancer	2023-12-01
ChiCTR2200055502	N/A	Recruiting	Breast Cancer	2022-12-31

Recent News Events

Date	Type	Title
12/10/2024	News Article	Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
12/10/2024	News Article	Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
10/29/2024	News Article	Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Verzenio® (abemaciclib) in Expanded Early Breast Cancer (EBC) Indication
10/24/2024	News Article	Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
05/15/2024	PubMed	Has the COVID-19 pandemic resulted in more advanced breast cancer? A hospital-based retrospective study.
05/15/2024	PubMed	Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
04/01/2024	PubMed	Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions